2/18/2010

Talecris Biotherapeutics received approval in Canada to launch Prolastin-C, a more concentrated version of its protein therapy for alpha1-antitrypsin deficiency, a genetic disorder. Prolastin-C takes half of the time required to administer the treatment.

Related Summaries